-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma to present olverembatinib POLARIS-2 phase 3 trial at ASCO 2026

PUBT·04/21/2026 23:02:45
Listen to the news
Ascentage Pharma to present olverembatinib POLARIS-2 phase 3 trial at ASCO 2026
  • Ascentage Pharma flagged six clinical-study abstracts selected for presentation at 2026 ASCO Annual Meeting in Chicago, scheduled May 29 to June 2, 2026.
  • Data will be presented in future, including three rapid oral presentations covering olverembatinib in leukemia settings, including combination use.
  • Program also includes lisaftoclax in a global Phase 3 registrational study in previously treated CLL/SLL.
  • Alrizomadlin results in pediatric relapsed or metastatic soft-tissue sarcomas will be presented, including monotherapy or combination with lisaftoclax.
  • Company positioned ASCO slate as reinforcing clinical value of its lead assets, supporting pipeline visibility with investors ahead of key readouts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260422-12114758), on April 21, 2026, and is solely responsible for the information contained therein.